Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06837480 · ClinicalTrials.gov registry record · NA

Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema

A NA study of Head and Neck Cancer and Lymphedema of the Head and Neck, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
2
Study locations

NCT06837480: Recruiting NA study of Head and Neck Cancer and Lymphedema of the Head and Neck, sponsored by Abramson Cancer Center at Penn Medicine.

NCT06837480 is a NA study of Head and Neck Cancer and Lymphedema of the Head and Neck that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 150 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (42% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06837480, a NA study of Head and Neck Cancer and Lymphedema of the Head and Neck, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
2
Study locations

Study Summary

The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for the treatment of chronic lymphedema in head and neck cancer (HNC) survivors. The objective of this study is to further investigate and confirm the positive effects of PBMT on HNC-related chronic lymphedema.

Primary Outcome

Head and Neck Lymphedema and Fibrosis Assessment Criteria. External lymphedema is measured by HN-LEF Assessment Criteria. The total external lymphedema severity score is calculated by summing the severity score of each site (total 9 sites, severity score ranging from 0-27). For each site, the severity of LEF includes no lymphedema (=0), mild (=1), moderate (=2), and severe (=3). Change in total severity of external lymphedema from baseline to 12-month post-intervention visits. A larger reducti

Interventions

  • DEVICE LTU-904 Portable Laser Therapy Unit (active laser device)
  • DEVICE LTU-904 Portable Laser Therapy Unit (sham/inactive laser device)

Study Locations (2)

Pennsylvania

  • University of Pennsylvania Abramson Cancer Center - Philadelphia

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-01-15
Est. Completion 2029-11-30
Phase NA

What NCT06837480 shows while recruiting

NCT06837480 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (42% lower).

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which LTU-904 Portable Laser Therapy Unit (active laser device) is the first listed.

NCT06837480 reports a single indexed study location in Pennsylvania, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06837480 about?

NCT06837480 is a clinical study titled "Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema". The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for th...

What is the current status of trial NCT06837480?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2026-01-15. Estimated completion is 2029-11-30.

What conditions does trial NCT06837480 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Lymphedema of the Head and Neck.

What interventions are being tested in trial NCT06837480?

The interventions under investigation include: LTU-904 Portable Laser Therapy Unit (active laser device) (DEVICE), LTU-904 Portable Laser Therapy Unit (sham/inactive laser device) (DEVICE).

Who is sponsoring clinical trial NCT06837480?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06837480 being conducted?

This trial has 2 study locations across Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06837480's enrollment target sits among peer trials

150 60th of 250 higher than 187 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06837480, the US trial registry maintained by the National Library of Medicine. NCT06837480 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.